The Latest Cardiac and Vascular News
INDIANAPOLIS, Aug. 4, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed – with or without pembrolizumab – as an initial treatment for patients with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC). The study met its primary endpoint, demonstrating a […]
The company plans to develop Lilly’s first-in-class clinical stage anti-angiopoietin-like 3/8 monoclonal antibody for treatment of atherosclerotic cardiovascular disease and potentially other conditions OXFORD, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Kyttaro announces that it has entered into an agreement for the worldwide exclusive license of an anti-angiopoietin-like (ANGPTL) 3/8 monoclonal antibody program developed by Eli Lilly and […]
– Revenue in the fourth quarter of 2021 increased 8 percent, driven by volume growth of 11 percent. Excluding COVID-19 antibodies, fourth-quarter 2021 revenue grew 6 percent. – Full-year 2021 revenue increased 15 percent, driven by volume growth of 16 percent. Excluding COVID-19 antibodies, full-year 2021 revenue grew 10 percent. – Key growth products, consisting […]
– Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction – Treatment of heart failure is an important unmet need with over half of those diagnosed dying within five years1 INGELHEIM, Germany & INDIANAPOLIS, […]
RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 14, 2019 /PRNewswire/ — Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined as non-inferiority for Tradjenta® (linagliptin) versus glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3P-MACE). CAROLINA is the […]
RIDGEFIELD, Conn. and INDIANAPOLIS, July 19, 2018 /PRNewswire/ — CARMELINA® (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE), with Tradjenta® demonstrating similar cardiovascular safety compared with placebo. Boehringer Ingelheim and Eli […]
